Table 2.

Outcomes of included studies investigating periprocedural antiplatelet use in patients with ischemic stroke who underwent acute mechanical thrombectomy.

Reference	sICH, n/N (%)	Mortality, n/N (%)	mRS (0–2), n/N (%)	sICH, OR (95% CI)	Mortality, OR (95% CI)	mRS (0–2), OR (95% CI)	sICH, aOR (95% CI)	Mortality, aOR (95% CI)	mRS (0–2), aOR (95% CI)
Broeg-Morvay et al. (22)	T = 3/50 (6%), C = 10/181 (6%)b	T = 9/50 (18%), C = 41/181 (23%)	T = 17/50 (34%), C = 83/181 (46%)	0.92 (0.24–3.46)	0.75 (0.34–1.67)	0.61 (0.32–1.17)	NR	NR	NR
Ernst et al. (24)	T = 7/54 (13%)c	T = 18/54 (33%)	T = 15/54 (28%)	NR	NR	NR	NR	NR	NR
Memon et al. (31)	T = 5/35 (14%)d	T = 8/35 (23%)	T = 21/35 (60%)	NR	NR	NR	NR	NR	NR
Mulder et al. (32)	T = 11/64 (17%), C = 7/169 (4%)d	T = 21/64 (33%), C = 28/169 (17%)	T = 15/64 (23%), C = 61/169 (36%)	4.80 (1.77–13.02)	2.46 (1.27–4.76)	0.54 (0.28–1.05)	NR	NR	NR
Pandhi et al. (39)	T = 4/71 (6%), C = 10/146 (7%)e	T = 18/71 (25%), C = 38/146 (26%)	T = 33/71 (50%), C = 64/146 (48%)	0.81 (0.25–2.68)	0.97 (0.50–1.85)	1.11 (0.63–1.97)	NR	NR	NR
Sugiura et al. (36)	T = 6/48 (13%), C = 4/156 (3%)f	NR	NR	5.43 (1.46–20.13)	NR	NR	8.03 (1.83–41.70)a	NR	NR

aOR, (adjusted) odds ratio; C, control; CI, confidence interval; mRS, modified Rankin Scale; NR, not reported; sICH, symptomatic intracranial hemorrhage; T, treated with antiplatelet agent; NIHSS, National Institutes of Health Stroke Scale.

^aAdjusted for glucose level and NIHSS at baseline.

^bPROACT-II definition (40).

^cIntracranial hemorrhage resulting in NIHSS increase of >4 or non-definable neurologic status with PH and severe mass effect or subarachnoid hemorrhage with hydrocephalus.

^dIntracranial hemorrhage resulting in NIHSS increase of ≥4.

^eSITS-MOST definition (41).

^fECASS-II definition (42).